The Effect of Intrawound Vancomycin Powder in Spine Surgery
Primary Purpose
Spine Disease
Status
Recruiting
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Vancomycin
Sponsored by
About this trial
This is an interventional prevention trial for Spine Disease
Eligibility Criteria
Inclusion Criteria:
- Patients requiring surgery due to any spine disease.
Exclusion Criteria:
- A previous history of infections at the spine surgical site.
- Biopsy procedure.
- Patients with a postoperative follow-up time of less than 12 weeks.
- Patients allergic to vancomycin.
- Patient is less than 18 years old.
Sites / Locations
- Windsor Regional Hospital - OuelletteRecruiting
- Cairo University HospitalsRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Active Comparator
Arm Label
Control
Vancomycin
Arm Description
Participants will not be receiving vancomycin.
For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.
Outcomes
Primary Outcome Measures
Rate of Infection
Number of patients with post-operative wound infection after spinal surgery (including the type of organism and duration of the procedure). Investigators will prospectively randomize all various types of spinal surgeries to patients who will receive intrawound vancomycin powder and control group who will not receive the powder and to see it's effect in reducing the post-surgical infection.
Secondary Outcome Measures
Complications
Number of patients who developed any complications related to the vancomycin.
Full Information
NCT ID
NCT04825522
First Posted
March 28, 2021
Last Updated
April 25, 2022
Sponsor
Windsor-Essex Compassionate Care Community
Collaborators
Cairo University
1. Study Identification
Unique Protocol Identification Number
NCT04825522
Brief Title
The Effect of Intrawound Vancomycin Powder in Spine Surgery
Official Title
The Effect of Intrawound Vancomycin Powder in Spine Surgery: A Prospective Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 27, 2021 (Actual)
Primary Completion Date
December 1, 2022 (Anticipated)
Study Completion Date
December 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Windsor-Essex Compassionate Care Community
Collaborators
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Problem: Postoperative wound infection following various spinal surgeries is a serious complication. The incidence of post-surgical wounds in spine surgery is high, and various researchers have reported different infection rates. In addition, increased healthcare costs, prolonged lengths of stay in hospital, and reduced quality of life as a result of surgical site infections (SSI) are also major concerns. Several methods for avoiding SSI, such as betadine irrigation, vacuum-assisted closure, and intra-wound vancomycin powder, have been used to reduce the rate of wound infection in spine surgery. Use of local vancomycin has been popular because of its protective effects and lower cost. According to some reports, prophylactic administration of intra-wound vancomycin powder before wound closure is an effective method for decreasing postoperative wound infection rates; however, other studies have revealed a non-significant effect of intra-wound vancomycin use for decreasing the postsurgical wound infection rate.
Solution: Therefore, the investigators will prospectively randomize all various types of spinal surgeries to patients who will receive intrawound vancomycin powder and control group who will not receive the powder and to see it's effect in reducing the post-surgical infection.
Detailed Description
Potential participants will be identified at the clinic, emergency department, or on the floor by history, clinical examination, and positive imaging findings. The surgeon will notify the study coordinator of the potential patient. The study coordinator will introduce the trial to the patient and obtain informed consent at the office during the clinic visit or his hospital stay. Patient's pre-operative data such as demographics (age and sex), presence of comorbidities like diabetes, ischemic heart disease, asthma patients on steroids, nutrition status using serum albumin level, and previous posterior spine surgical procedures at the operative level will be collected once the patient admitted prior to the procedure. The study coordinator will enroll the patient into the trial, and provide the appropriate intervention (vancomycin application, or no application) using the closed envelope technique of randomization to the neurosurgeon performing the procedure. Patients will also be blinded to avoid the placebo effect. All patients will receive the standard systemic antibiotic prophylaxis. The duration of the procedure, estimated blood loss, type of the procedure (instrumented versus non-instrumented) and the number of levels will be recorded. After the intervention, wound infections will be monitored during a follow-up period of 12 weeks from the date of surgery. Cultured organisms and subsequent treatments will be recorded. The primary outcome is the incidence of infection (either in-patient or in the follow-up). The secondary outcome is the development of other complications including Vancomycin related.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spine Disease
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Experimental Group: For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.
Control Group: Will not receive any extra treatment.
Masking
Participant
Masking Description
The patients will not know if they received vancomycin or not.
Allocation
Randomized
Enrollment
1643 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Control
Arm Type
No Intervention
Arm Description
Participants will not be receiving vancomycin.
Arm Title
Vancomycin
Arm Type
Active Comparator
Arm Description
For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.
Intervention Type
Drug
Intervention Name(s)
Vancomycin
Other Intervention Name(s)
Treatment group
Intervention Description
During spinal surgery, participants will receive intrawound vancomycin powder in their wound before closure.
Primary Outcome Measure Information:
Title
Rate of Infection
Description
Number of patients with post-operative wound infection after spinal surgery (including the type of organism and duration of the procedure). Investigators will prospectively randomize all various types of spinal surgeries to patients who will receive intrawound vancomycin powder and control group who will not receive the powder and to see it's effect in reducing the post-surgical infection.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Complications
Description
Number of patients who developed any complications related to the vancomycin.
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients requiring surgery due to any spine disease.
Exclusion Criteria:
A previous history of infections at the spine surgical site.
Biopsy procedure.
Patients with a postoperative follow-up time of less than 12 weeks.
Patients allergic to vancomycin.
Patient is less than 18 years old.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mohamed Soliman, MSc, MD
Phone
17329241637
Email
msolim8@uwo.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Abdalla Shamisa, FRCSC
Email
ashamisa@yahoo.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohamed Soliman, MD
Organizational Affiliation
Western University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Windsor Regional Hospital - Ouellette
City
Windsor
State/Province
Ontario
ZIP/Postal Code
N9A 1E1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abdalla Shamisa, MD
Email
ashamisa@yahoo.ca
First Name & Middle Initial & Last Name & Degree
Balraj Jhawar, MD
Email
bsjahwar@gmail.com
Facility Name
Cairo University Hospitals
City
Cairo
ZIP/Postal Code
11562
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Noha Assem, MD
Email
kasralainirec@gmail.com
First Name & Middle Initial & Last Name & Degree
Helmy El-Dessouky, MD
First Name & Middle Initial & Last Name & Degree
Wael El Mahdy, MD, FRCS
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
29178308
Citation
Xie LL, Zhu J, Yang MS, Yang CY, Luo SH, Xie Y, Pu D. Effect of Intra-wound Vancomycin for Spinal Surgery: A Systematic Review and Meta-analysis. Orthop Surg. 2017 Nov;9(4):350-358. doi: 10.1111/os.12356.
Results Reference
background
PubMed Identifier
25608241
Citation
Tomov M, Mitsunaga L, Durbin-Johnson B, Nallur D, Roberto R. Reducing surgical site infection in spinal surgery with betadine irrigation and intrawound vancomycin powder. Spine (Phila Pa 1976). 2015 Apr 1;40(7):491-9. doi: 10.1097/BRS.0000000000000789.
Results Reference
background
PubMed Identifier
24838506
Citation
Evaniew N, Khan M, Drew B, Peterson D, Bhandari M, Ghert M. Intrawound vancomycin to prevent infections after spine surgery: a systematic review and meta-analysis. Eur Spine J. 2015 Mar;24(3):533-42. doi: 10.1007/s00586-014-3357-0. Epub 2014 May 18.
Results Reference
background
PubMed Identifier
28207669
Citation
Hey HWD, Thiam DW, Koh ZSD, Thambiah JS, Kumar N, Lau LL, Liu KG, Wong HK. Is Intraoperative Local Vancomycin Powder the Answer to Surgical Site Infections in Spine Surgery? Spine (Phila Pa 1976). 2017 Feb 15;42(4):267-274. doi: 10.1097/BRS.0000000000001710.
Results Reference
background
PubMed Identifier
21600853
Citation
O'Neill KR, Smith JG, Abtahi AM, Archer KR, Spengler DM, McGirt MJ, Devin CJ. Reduced surgical site infections in patients undergoing posterior spinal stabilization of traumatic injuries using vancomycin powder. Spine J. 2011 Jul;11(7):641-6. doi: 10.1016/j.spinee.2011.04.025. Epub 2011 May 19.
Results Reference
background
Learn more about this trial
The Effect of Intrawound Vancomycin Powder in Spine Surgery
We'll reach out to this number within 24 hrs